Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PTGX Protagonist Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: PTGX
Price (delayed)
$51.05
Market cap
$3.16B
P/E Ratio
56.72
Dividend/share
N/A
EPS
$0.9
Enterprise value
$3.04B
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2
Highlights
The quick ratio has grown by 33% from the previous quarter and by 4.9% YoY
The equity has grown by 23% YoY and by 2% from the previous quarter
PTGX's P/E is 150% above its last 4 quarters average of 22.5
Protagonist Therapeutics's EPS has shrunk by 80% QoQ and by 66% YoY
Key stats
What are the main financial stats of PTGX
Market
Valuations
Earnings
Shares outstanding
61.98M
Market cap
$3.16B
Enterprise value
$3.04B
Price to earnings (P/E)
56.72
Price to book (P/B)
4.55
Price to sales (P/S)
15.47
EV/EBIT
53.18
EV/EBITDA
50.62
EV/Sales
14.61
Revenue
$207.8M
Gross profit
$207.8M
Operating income
$27.22M
Net income
$56.19M
EBIT
$57.09M
EBITDA
$59.97M
Free cash flow
$335.29M
Per share
Balance sheet
Liquidity
EPS
$0.9
EPS diluted
$0.78
Free cash flow per share
$5.33
Book value per share
$11.23
Revenue per share
$3.3
TBVPS
$11.79
Total assets
$742.13M
Total liabilities
$53.08M
Debt
$11.36M
Equity
$689.05M
Working capital
$570.75M
Debt to equity
0.02
Current ratio
17.26
Quick ratio
16.36
Net debt/EBITDA
-2.14
Margins
Efficiency
Dividend
EBITDA margin
28.9%
Gross margin
100%
Net margin
27%
Operating margin
13.1%
Return on assets
8.3%
Return on equity
9.2%
Return on invested capital
12.3%
Return on capital employed
8.1%
Return on sales
27.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PTGX stock price
How has the Protagonist Therapeutics stock price performed over time
Intraday
0.71%
1 week
-7.54%
1 month
-0.02%
1 year
47.97%
YTD
32.25%
QTD
-7.64%
Financial performance
How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$207.8M
Gross profit
$207.8M
Operating income
$27.22M
Net income
$56.19M
Gross margin
100%
Net margin
27%
PTGX's operating income has dropped by 89% since the previous quarter and by 82% year-on-year
The net income has dropped by 80% since the previous quarter and by 65% year-on-year
The operating margin has plunged by 77% from the previous quarter and by 72% YoY
The net margin has dropped by 57% since the previous quarter and by 48% year-on-year
Price vs fundamentals
How does PTGX's price correlate with its fundamentals
Growth
What is Protagonist Therapeutics's growth rate over time
Valuation
What is Protagonist Therapeutics stock price valuation
P/E
56.72
P/B
4.55
P/S
15.47
EV/EBIT
53.18
EV/EBITDA
50.62
EV/Sales
14.61
PTGX's P/E is 150% above its last 4 quarters average of 22.5
Protagonist Therapeutics's EPS has shrunk by 80% QoQ and by 66% YoY
The equity has grown by 23% YoY and by 2% from the previous quarter
The P/B is 19% more than the 5-year quarterly average of 3.8 and 10% more than the last 4 quarters average of 4.1
The stock's price to sales (P/S) is 85% less than its 5-year quarterly average of 102.2 but 75% more than its last 4 quarters average of 8.8
Protagonist Therapeutics's revenue has shrunk by 52% QoQ and by 34% YoY
Efficiency
How efficient is Protagonist Therapeutics business performance
The ROIC has plunged by 87% YoY and by 81% from the previous quarter
The company's return on equity has shrunk by 81% QoQ and by 79% YoY
PTGX's ROA has dropped by 80% since the previous quarter and by 79% year-on-year
Protagonist Therapeutics's return on sales has shrunk by 57% QoQ and by 48% YoY
Dividends
What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PTGX.
Financial health
How did Protagonist Therapeutics financials performed over time
The current ratio is up by 38% since the previous quarter and by 10% year-on-year
The quick ratio has grown by 33% from the previous quarter and by 4.9% YoY
The debt is 98% smaller than the equity
The equity has grown by 23% YoY and by 2% from the previous quarter
The debt has grown by 4.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.